Acadia Healthcare Company, Inc. (NASDAQ: ACHC) today announced the opening of its newest acute care hospital, Coachella Valley Behavioral Health, located at 81555 JFK Court in Indio, California. A ribbon-cutting ceremony was held today to mark its grand opening with…
alk Free’s 2023 Global Slavery Index estimates that almost 50 million people around the world are being coerced, threatened or deceived in order to be exploited and have their freedom undermined. Modern slavery is a broad term that includes human…
Medibank has released data on the top hospital claims for 2023, as well as the most expensive claims paid this year. Medibank can reveal that the highest paid claim was $321,000 for neonatal services, with a $274,000 claim for tracheostomy…
ImmunoPrecise Antibodies Ltd. (NASDAQ: IPA) (“ImmunoPrecise” or “IPA” or the “Company”), today announced the closing of its $1.265 million underwritten public offering of 1,265,000 common shares, including 165,000 common shares issued pursuant to the full exercise by the underwriter of…
RevBio, Inc., announced that it has received approval from the U.S. Food and Drug Administration to start a 20-patient pilot clinical trial to examine the safety and efficacy of the company’s bone adhesive biomaterial called TETRANITE® to immediately stabilize and fixate…
bluebird bio, Inc. (Nasdaq: BLUE) (“bluebird bio” or “bluebird”) today announced the U.S. Food and Drug Administration (FDA) has approved LYFGENIA™ (pronounced as ‘lif-JEN-ee-uh’) (lovotibeglogene autotemcel), also known as lovo-cel, for the treatment of sickle cell disease in patients ages 12…
Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), presented today positive results from the Phase III INAVO120 study evaluating inavolisib in combination with palbociclib (Ibrance®) and fulvestrant as a first-line treatment for people with PIK3CA-mutated, hormone receptor…
Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today positive long-term follow-up data from the pivotal, Phase III KATHERINE study in people with HER2-positive early-stage breast cancer (eBC) who have residual invasive disease following neoadjuvant…
CB Insights named BostonGene, a leading provider of AI-driven molecular and immune profiling solutions, to its fifth-annual Digital Health 50 showcasing the 50 most promising private digital health companies of 2023. The 50 winners, representing eight countries across the globe, were selected from…
Thousands of ambulatory healthcare professionals from across the US traveled to Orlando last week to gather insights on navigating the ever-changing healthcare landscape, including how to leverage artificial intelligence (AI) to reduce provider burnout and maximize outcomes. Held Nov. 29…
–Pfizer Inc. (NYSE:PFE) today announced the European Commission (EC) has granted conditional marketing authorization for ELREXFIO® (elranatamab). ELREFXIO is a targeted immunotherapy for the treatment of adult patients with relapsed and refractory multiple myeloma (RRMM) who have received at least three prior…
Merck (NYSE: MRK), known as MSD outside of the United States and Canada, and Eisai today announced that the Phase 3 LEAP-001 trial evaluating KEYTRUDA, Merck’s anti-PD-1 therapy, plus LENVIMA, the orally available multiple receptor tyrosine kinase inhibitor discovered by…